A
Antag Therapeutics
Antag Therapeutics – Therapeutic peptides for the treatment of obesity
About Antag Therapeutics
Antag Therapeutics is a pioneering biotech company focused on developing innovative therapies for metabolic diseases, particularly obesity and type 2 diabetes. Operating in the global healthcare market, Antag Therapeutics serves patients suffering from these conditions, which are often exacerbated by excessive caloric intake and inactive lifestyles. The company employs a business model centered on the research, development, and commercialization of novel treatment approaches that address the shortcomings of current pharmacological interventions, such as tolerability issues, weight gain, and loss of efficacy over time. Antag Therapeutics generates revenue through the development and licensing of its proprietary compounds, as well as potential partnerships with larger pharmaceutical companies. The company's leadership team boasts extensive experience in biotech, venture capital investment, and the commercialization of innovative medical solutions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Copenhagen, Denmark
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 78.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Weight Management, Nutrition, Spinout, Metabolism, Biotech and Pharma, Hard Tech, Woman Founder, Longevity, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Dec 2024 | $88M | $352M | Pictet · Longview Ventures · Export and Investment Fund of Denmark · SR One | ↗ |
| LATE VCOther financing | Jun 2020 | $3.5M | $14M | Broadview Ventures | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Antag Therapeutics is 3.8K monthly website visits, up 192.3% over the last three months. Antag Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Novo Seeds
Novo Ventures
Versant Ventures
Pictet
Longview Ventures
Export and Investment Fund of Denmark
SR One
Novo Holdings
Dawn Biopharma
Series B and later1 investor entered at this stage
Broadview Ventures
Other known investors1 additional known investor
Technical University of Denmark
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Antag Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Antag Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.